Business
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
VivoSim’s NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy resultsSAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the availability of an AI prediction tool leveraging its NAMkind™ intestinal models to accurately predict the potential of a given drug compound to cause diarrhea in patients. The tool int
About this update from Vivosim Labs, Inc.
[{"type":"image","alt":"VivoSim Labs, Inc.","displaySize":"","headline":null,"caption":"VivoSim Labs, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":133,"url":"https://media.zenfs.com/en/globenewswire.com/e54b5ed2b47b2a40c4e408056374d68a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lgsmbcMDQuxqoRZ7Mq0ICg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4Ng--/https://media.zenfs.com/en/globenewswire.com/e54b5ed2b47b2a40c4e408056374d68a","width":300,"height":133}},"lazy":false},{"type":"text","content":"VivoSim’s NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results","length":103,"tagName":"p"},{"type":"text","content":"SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the availability of an AI prediction tool leveraging its NAMkind™ intestinal models to accurately predict the potential of a given drug compound to cause diarrhea in patients. The tool integrates its proprietary NAMkind™ ileum and colon tissues with advanced machine‑learning analytics to identify drug‑induced disruptions to intestinal epithelial integrity and function. Tissue-based assay data is used to train an AI predictive model in a process VivoSim has named VitroSense™.","length":693,"tagName":"p"},{"type":"text","content":"The model was built using a training set of dozens of compounds. Using high-quality real-world 3d NAM assay results generated from the set of training compounds, the model attained a predictive accuracy of 96% for potential diarrhea. This success represents a significant step forward for the field, demonstrating the value of combining data from VivoSim’s complex 3D cell-based assays with machine learning approaches. For a novel compound being investigated for the first time, such as from a client, multiple data endpoints are measured in NAMkind™ intestine assays and these data are fed into the AI prediction model to generate an overall assessment of diarrhea risk. Because so many cancer drugs have dose-limiting toxicities, the Company believes that this breakthrough over reliance on animal models can have a transformational impact on the next generation of cancer treatments.","length":887,"tagName":"p"},{"type":"text","content":...